Inaxaplin - Vertex Pharmaceuticals
Alternative Names: VX-147Latest Information Update: 17 Feb 2025
Price :
$50 *
At a glance
- Originator Vertex Pharmaceuticals
- Class Small molecules; Urologics
- Mechanism of Action Apolipoprotein L1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Kidney disorders
- Phase II Focal segmental glomerulosclerosis
Most Recent Events
- 10 Feb 2025 Vertex announces intention to submit application for accelerated approval for Kidney disorders in the US
- 04 Feb 2025 Vertex Pharmaceuticals initiates phase IIb AMPLIFIED clinical trials in Kidney disorders in USA (PO) (NCT06794996)
- 12 Jan 2025 Vertex Pharmaceuticals plans a phase IIb AMPLIFIED trial for APOL1-Mediated Kidney Disease